ホームページ GPCR & G Protein Glucagon Receptor

Glucagon Receptor

亜型選択性的な製品

Glucagon Receptor製品

  • All (18)
  • Glucagon Receptor拮抗剤(1)
  • Glucagon Receptor作動薬(7)
  • Glucagon Receptorモジュレータ(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
J Immunother Cancer, 2024, 12(3)e008431
Front Endocrinol (Lausanne), 2024, 15:1395028
Mol Metab, 2023, 76:101794
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
E1173 V-0219 V-0219 is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R), can be used for obesity-associated diabetes research.
S3734 Albiglutide Fragment Albiglutide fragment is one copy of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36).
S0555 Adomeglivant Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.
S9697 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
S9935 Teduglutide Teduglutide (ALX-0600, Gattex, Revestive, TAK 633) is an analogue of human glucagon-like peptide-2 (GLP-2) and binds to the GLP-2 receptors. Teduglutide prolongs the intestinotrophic properties of GLP-2 in animal models.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
J Immunother Cancer, 2024, 12(3)e008431
Front Endocrinol (Lausanne), 2024, 15:1395028
Mol Metab, 2023, 76:101794
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
S9697 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
S0555 Adomeglivant Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
J Immunother Cancer, 2024, 12(3)e008431
Front Endocrinol (Lausanne), 2024, 15:1395028
Mol Metab, 2023, 76:101794
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
S9697 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
E1173 V-0219 V-0219 is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R), can be used for obesity-associated diabetes research.
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.

Glucagon Receptor阻害剤の選択性比較

Tags: Glucagon Receptor antagonist | Glucagon Receptor agonist | Glucagon Receptor Inhibition| Glucagon Receptor Activation| Glucagon Receptor antagonist | Glucagon Receptor agonist | Glucagon Receptor Activity